Michael Obuchowski News
-
As Apple Inc. Chief Executive Officer Tim Cook takes the stage at this year’s shareholder meeting, he may not get the reception he received in 2012, when investors lauded the company’s performance and rising shares.
-
A band of Apple Inc.’s most bullish fans on Wall Street are growing increasingly bearish over concerns that holiday iPhone sales have been weak and that the company needs new breakthrough products to fend off rivals Google Inc. and Samsung Electronics Co.
-
Hewlett-Packard Co.’s $8.8 billion writedown tied to the purchase of software maker Autonomy Corp. is fueling concern that Chief Executive Officer Meg Whitman and her board aren’t up to the task of engineering a turnaround.
-
Apple Inc. shares fell 4.3 percent after quarterly iPhone sales missed analysts’ projections, underscoring the computer maker’s reliance on the smartphone.
-
The Standard & Poor’s 500 Index erased gains in the final hour of trading as a rally in bank and industrial shares wasn’t enough to overcome disappointing results at Apple Inc. and an unexpected drop in new home sales.
-
Apple Inc. has its biggest gain in more than three years after reporting that demand for the iPhone in China fueled a 94 percent surge in quarterly profit. That eased concerns that had cut shares 12 percent in two weeks.
-
Takeda Pharmaceutical Co. is pursuing its biggest acquisition after destroying more value for shareholders than any drugmaker and hoarding the most cash.
-
As Facebook Inc. prepares its initial public offering, traders are boosting the cost of bearish options at a record rate for LinkedIn Corp. and four other Internet companies that sold shares in the past year.
-
The rally in solar shares after Japan ’s atomic accident may fizzle because the crisis won’t quickly boost demand for renewable power, investors including First Empire Asset Management’s Michael Obuchowski said.
-
Henri Termeer , a biotech industry pioneer and chief executive officer at Genzyme Corp ., is on the verge of losing control of the company he transformed from a start-up in 1983 into a cutting-edge drugmaker with $4.5 billion in annual sales.
|
|
Most Popular on Bloomberg
|
|
Michael Obuchowski Videos
|
|
Rate this Page